Blood test may predict brain tumor return
NCT ID NCT07282470
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at epigenetic changes in meningioma tumors and blood samples to find markers that could predict if the tumor will come back after surgery. Researchers will analyze tissue from past patients and collect blood from new patients. The goal is to improve personalized care for people with this common brain tumor.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a blood test that helps doctors predict which meningiomas are likely to come back after surgery.
- What could go wrong
- This is an observational study, not a treatment trial. The findings may not lead to immediate changes in patient care, and the epigenetic markers may not prove reliable in larger, diverse groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MENINGIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fondazione IRCCS Istituto Neurologico Carlo Besta
RECRUITINGMilan, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could blocking a Tumor's blood supply shrink brain meningiomas?
- New platform trial takes on NF2 tumors with multiple drug strategies
- Could a cancer drug shrink brain tumors and save hearing in a rare nerve disorder?
- Drug combo aims to shrink NF2 tumors and save hearing
- Radiation's hidden toll on the brain: new study maps cognitive changes to protect patients
- New combo aims to stall aggressive brain tumors when surgery and radiation fail